Please ensure Javascript is enabled for purposes of website accessibility

Mehmet Akce

HCRN-GI24-671

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab (STRIDE) Plus Gemcitabine and Cisplatin (GEMCIS) in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma (cHCC-CCA)
Status
Cancer Types
Liver and Bile Duct
Locations

HCRN-GI23-621

A phase II study of pemigatinib plus durvalumab (MEDI4736) in previously treated advanced intrahepatic cholangiocarcinoma patients with FGFR-2 fusion or rearrangement
Status
Cancer Types
Liver and Bile Duct
Locations